ID Biomedical and Tm Technologies settle claims:
This article was originally published in Clinica
Executive Summary
ID Biomedical and Tm Technologies have agreed in principle to settle their claims (see Clinica No 647, p 16). As part of the expected settlement, Tm will issue to ID Biomedical 1,330,000 shares of Tm stock and dismiss and release all litigation claims between the companies. The agreement is dependent on the approval of the Vancouver stock exchange and conditions must be satisfied by the beginning of December.